Paradigm will use the proceeds to refinance its existing credit facility and primarily expand its domestic commercial operations for its coflex Interlaminar stabilization device for patients with spinal stenosis. The device was approved by the FDA in 2012 and is sold in more than 50 countries.
More Articles on Devices:
Is Biomet Next to Form IPO?
Bioventus Names VP of Global Marketing
Aurora Spine Appoints New VP of Sales
